VACCINE BREAKTHROUGH: Personalized cancer treatment takes major leap

• Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157/V940) combined with Keytruda met primary goals in a Phase 3 melanoma trial, reducing cancer recurrence or death.
• Moderna shares surged over 129% in one week following the announcement, with Merck also seeing a 12% jump.
• FDA approval for the cancer vaccine is anticipated next year, with the first mRNA-based flu vaccine (mRESVIA) already approved for individuals 50 and older.
• Moderna plans to expand its mRNA platform to address kidney cancer, other severe cancers, rare genetic diseases, and autoimmune diseases, aiming for long-term growth and profitability.

Moderna CEO Stéphane Bancel discussed a significant cancer vaccine breakthrough in partnership with Merck, with Phase 3 melanoma trial results meeting primary goals. This news sent Moderna's shares soaring, highlighting the transformative potential of mRNA technology beyond infectious diseases into oncology, rare genetic diseases, and autoimmune conditions. The company also received FDA approval for its first mRNA-based flu vaccine.